- Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance
-
Park SH, Kim B
- KMID: 2505839
- J Liver Cancer.
- 2020 Mar;20(1):25-31.
- doi: 10.17998/jlc.20.1.25
Hepatocellular carcinoma (HCC) surveillance is recommended when the annual incidence of HCC exceeds 1.5%. In 2018, several international guidelines included alternative surveillance modalities, such as computed tomography and magnetic resonance... -
- CITED
-
- Close
- SHARE
-
- Close
- Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma
-
Yu SJ, Greten TF
- KMID: 2505837
- J Liver Cancer.
- 2020 Mar;20(1):1-16.
- doi: 10.17998/jlc.20.1.1
Use of immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC) has been partially successful. However, most HCC patients do not respond to immunotherapy. HCC has been shown to induce several... -
- CITED
-
- Close
- SHARE
-
- Close
- Gut-microbiome Taxonomic Profiling as Non-invasive Biomarkers for the Early Detection of Alcoholic Hepatocellular Carcinoma
-
Seok J, Suk KT
- KMID: 2505840
- J Liver Cancer.
- 2020 Mar;20(1):32-40.
- doi: 10.17998/jlc.20.1.32
Background/Aims: Hepatocellular carcinoma (HCC) is a prevalent form of primary liver cancer and the fifth leading cause of worldwide cancer mortality. Though early diagnosis of HCC is important, so far... -
- CITED
-
- Close
- SHARE
-
- Close
- A Survey of Liver Cancer Specialists’ Views on the National Liver Cancer Screening Program in Korea
-
Sohn W, Lee YS, Lee JG, An J, Jang ES, Lee DH, Sinn DH
- KMID: 2505842
- J Liver Cancer.
- 2020 Mar;20(1):53-59.
- doi: 10.17998/jlc.20.1.53
Background/Aims: To reduce the cancer burden, the Korean government initiated the National Cancer Control Plan including the National Liver Cancer Screening Program (NLCSP). Ultrasonography examinations and α-fetoprotein tests at six-month... -
- CITED
-
- Close
- SHARE
-
- Close
- Histopathological Variants of Hepatocellular Carcinomas: an Update According to the 5th Edition of the WHO Classification of Digestive System Tumors
-
Kim H, Jang M, Park YN
- KMID: 2505838
- J Liver Cancer.
- 2020 Mar;20(1):17-24.
- doi: 10.17998/jlc.20.1.17
Hepatocellular carcinoma (HCC) is heterogeneous in pathogenesis, phenotype and biological behavior. Various histopathological features of HCC had been sporadically described, and with the identification of common molecular alterations of HCC... -
- CITED
-
- Close
- SHARE
-
- Close
- Combined Transarterial Chemoembolization and External Beam Radiotherapy in a Patient with Recurrent Huge Hepatocellular Carcinoma after Hepatic Resection
-
Yu J, Jung J, Yoon SM
- KMID: 2505848
- J Liver Cancer.
- 2020 Mar;20(1):90-97.
- doi: 10.17998/jlc.20.1.90
The optimal treatment strategy for unresectable huge hepatocellular carcinoma (HCC) is yet to be established. Non-surgical monotherapy demonstrated insufficient oncologic outcomes in previously reported studies. To improve the clinical outcomes... -
- CITED
-
- Close
- SHARE
-
- Close
- Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation
-
Lee SK, Jang JW, Nam H, Sung PS, Bae SH, Choi JY, Yoon SK
- KMID: 2505847
- J Liver Cancer.
- 2020 Mar;20(1):84-89.
- doi: 10.17998/jlc.20.1.84
The efficacy and safety of sequential systemic therapy for the treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) are not well established. This study describes a successful experience... -
- CITED
-
- Close
- SHARE
-
- Close
- Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
-
Kim J, Chang JW, Park JY
- KMID: 2505845
- J Liver Cancer.
- 2020 Mar;20(1):72-77.
- doi: 10.17998/jlc.20.1.72
Over the past decade, standard first-line systemic treatment of advanced hepatocellular carcinoma (HCC) has been based on sorafenib, a multi-kinase inhibitor. Regorafenib, another tyrosine kinase inhibitor, is the only second-line... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatocellular Carcinoma in Korea Between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry
-
Yoon JS, Lee HA, Park JY, Kim BH, Lee IJ, Chon YE, Hong SK, Lee DH, Kong HJ, Won YJ, Kim E, Lee JH
- KMID: 2505841
- J Liver Cancer.
- 2020 Mar;20(1):41-52.
- doi: 10.17998/jlc.20.1.41
Backgrounds/Aims: Backgrounds/Aims: In Korea, hepatocellular carcinoma (HCC) is the sixth most common cancer and results in the second-highest cancer death rate among all cancers. We aimed to describe the characteristics... -
- CITED
-
- Close
- SHARE
-
- Close
- Lipiodol Pneumonitis Following Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
-
Kim S, Kim HY, Lee SL, Ku YM, Won YD, Kim CW
- KMID: 2505843
- J Liver Cancer.
- 2020 Mar;20(1):60-66.
- doi: 10.17998/jlc.20.1.60
Transcatheter arterial chemoembolization (TACE) is a useful palliative therapeutic modality for hepatocellular carcinoma (HCC). Postembolization syndromes, such as fever, abdominal pain, and elevated liver enzyme levels are commonly known complications... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Treated by Hepatic Arterial Infusion Chemotherapy and Radiotherapy
-
Lee JY, Yoo JJ, Chun SJ, Bae SH, Lee JM, Kim SG, Kim YS
- KMID: 2505846
- J Liver Cancer.
- 2020 Mar;20(1):78-83.
- doi: 10.17998/jlc.20.1.78
Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). Additionally, hepatic arterial infusion chemotherapy has been used as a treatment option for advanced HCC.... -
- CITED
-
- Close
- SHARE
-
- Close
- Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review
-
Lim DH, Yoon JH, Jun DW, Lee OY, Yoon BC, Lee HR, Kim KS, Choi HS
- KMID: 2505844
- J Liver Cancer.
- 2020 Mar;20(1):67-71.
- doi: 10.17998/jlc.20.1.67
Tyrosine kinase inhibitors are widely used as targeted treatments for various malignancies. Sorafenib is an orally active tyrosine kinase inhibitor that blocks the signaling pathways of several growth factors. Its... -
- CITED
-
- Close
- SHARE
-
- Close
